Ontology highlight
ABSTRACT:
SUBMITTER: Feng Q
PROVIDER: S-EPMC4995153 | biostudies-literature | 2017 Mar
REPOSITORIES: biostudies-literature
Feng Q Q Wei W Q WQ Chung C P CP Levinson R T RT Bastarache L L Denny J C JC Stein C M CM
The pharmacogenomics journal 20160223 2
Statins (HMG-CoA reductase inhibitors) lower low-density lipoprotein cholesterol (LDL-C) and prevent cardiovascular disease. However, there is wide individual variation in LDL-C response. Drugs targeting proprotein convertase subtilin/kexin type 9 (PCSK9) lower LDL-C and will be used with statins. PCSK9 mediates the degradation of LDL receptors (LDLRs). Therefore, a greater LDL-C response to statins would be expected in individuals with PCSK9 loss-of-function (LOF) variants because LDLR degradat ...[more]